Navigation Links
BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition
Date:12/5/2008

BIRMINGHAM, Ala., Dec. 5 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) announced today that the Company will present pre-clinical data on Forodesine HCl and BCX-4208, and clinical data on BCX-4208 at the 50th American Society of Hematology (ASH) Annual Meeting and Exposition being held in San Francisco, CA from December 6-9, 2008. Forodesine HCl and BCX-4208 are clinical-stage purine nucleoside phosphorylase (PNP) inhibitors.

The schedule for BioCryst's poster presentations at ASH is as follows:

BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor is a Novel, Potent Orally Active Anti T- and B-Cell Agent (Poster # 1547)

Saturday, December 6, 2008, 5:30 p.m. - 7:30 p.m. Pacific Time; Hall A

A Phase II Study of the Purine Nucleoside Phosphorylase (PNP) Inhibitor RO5092888 (BCX-4208) in Patients with Moderate to Severe Chronic Plaque Psoriasis: Safety, Tolerability and Lymphocyte Effects (Poster # 2583)

Sunday, December 7, 2008, 6:00 p.m. - 8:00 p.m. Pacific Time; Hall A

In-Vitro Efficacy of the Deoxyguanoside Analogs Forodesine (BCX-1777) and ARA-G in Pediatric Acute Lymphoblastic Leukemia Cells (Poster # 1925)

Sunday, December 7, 2008, 6:00 p.m. - 8:00 p.m. Pacific Time; Hall A

About BioCryst

BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. In addition, the Company has a pre-clinical portfolio of novel compounds, directed against infectious, cardi
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
2. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
3. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
4. BioCryst to Present at the JMP Healthcare Focus Conference
5. BioCryst to Present at UBS 2008 Global Life Sciences Conference
6. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
7. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
8. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
9. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
10. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
11. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Reportlinker.com announces that a new market research report is ... - technologies, markets and companies ... Up-to-date on-stop information on gene therapy with 72 tables and ... - 700 selected references from the literature ...
... announces that a new market research report is ... applications, markets and companies ... creation and utilization of materials, devices, and systems ... scale (a nanometer is one billionth of a ...
... strip with two surfaces but only one side, has been ... German mathematician August Mbius. As artist M.C. Escher so vividly ... traverse the "inside" and "outside" surfaces of a Mbius strip ... searching for an example of Mbius symmetry in natural materials ...
Cached Biology Technology:Reportlinker Adds Gene Therapy - technologies, markets and companies 2Reportlinker Adds Gene Therapy - technologies, markets and companies 3Reportlinker Adds Gene Therapy - technologies, markets and companies 4Reportlinker Adds Gene Therapy - technologies, markets and companies 5Reportlinker Adds Gene Therapy - technologies, markets and companies 6Reportlinker Adds Gene Therapy - technologies, markets and companies 7Reportlinker Adds Gene Therapy - technologies, markets and companies 8Reportlinker Adds Gene Therapy - technologies, markets and companies 9Reportlinker Adds Gene Therapy - technologies, markets and companies 10Reportlinker Adds Gene Therapy - technologies, markets and companies 11Reportlinker Adds Gene Therapy - technologies, markets and companies 12Reportlinker Adds Gene Therapy - technologies, markets and companies 13Reportlinker Adds Gene Therapy - technologies, markets and companies 14Reportlinker Adds Gene Therapy - technologies, markets and companies 15Reportlinker Adds Gene Therapy - technologies, markets and companies 16Reportlinker Adds Gene Therapy - technologies, markets and companies 17Reportlinker Adds Gene Therapy - technologies, markets and companies 18Reportlinker Adds Gene Therapy - technologies, markets and companies 19Reportlinker Adds Gene Therapy - technologies, markets and companies 20Reportlinker Adds Gene Therapy - technologies, markets and companies 21Reportlinker Adds Nanobiotechnologies- applications, markets and companies 2Reportlinker Adds Nanobiotechnologies- applications, markets and companies 3Reportlinker Adds Nanobiotechnologies- applications, markets and companies 4Reportlinker Adds Nanobiotechnologies- applications, markets and companies 5Reportlinker Adds Nanobiotechnologies- applications, markets and companies 6Reportlinker Adds Nanobiotechnologies- applications, markets and companies 7Reportlinker Adds Nanobiotechnologies- applications, markets and companies 8Reportlinker Adds Nanobiotechnologies- applications, markets and companies 9Reportlinker Adds Nanobiotechnologies- applications, markets and companies 10Reportlinker Adds Nanobiotechnologies- applications, markets and companies 11Reportlinker Adds Nanobiotechnologies- applications, markets and companies 12Reportlinker Adds Nanobiotechnologies- applications, markets and companies 13Reportlinker Adds Nanobiotechnologies- applications, markets and companies 14Reportlinker Adds Nanobiotechnologies- applications, markets and companies 15Reportlinker Adds Nanobiotechnologies- applications, markets and companies 16
(Date:7/9/2014)... of increasing concern about the prevalence of antibiotic-resistant ... promising new pathway to disabling disease: blocking bacteria,s ... scientists showed how bacterial siderophore, a small molecule, ... fan bacterial growth as well as how ... infection process. Their findings appear in a recent ...
(Date:7/9/2014)... season upon us, many backyard cooks are turning to ... dogs. But low fat can sometimes mean low satisfaction. ... texture problem in low-fat wieners that are made with ... published in ACS, Journal of Agricultural and Food ... that hot-dog consumers have come to expect just the ...
(Date:7/9/2014)... re-examination of a sparrow-sized fossil from China challenges the ... dinosaurs that gained the ability to fly. The birdlike ... but much rather the remains of a tiny tree-climbing ... of the Dinosaur Museum in Blanding, Utah, and Alan ... appears in Springer,s Journal of Ornithology . , ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2Researchers declassify dinosaurs as being the great-great-grandparents of birds 2
... always been what they are today, particularly for omnivores. ... tigers and other big cats as examples. Other mammals ... on a diet of leaves, shoots, fruits and bark. ... addition to meat, the situation wasn,t always that way, finds ...
... , This release is available in ... the US and Europe harbour more plant species than ... closer related to each other and often share similar ... environmental impacts than rural ecosystems. This is concluded by ...
... 18/04/12 - Technology has transformed the way humans interact with ... ideas that will drive growth in marine and maritime sectors ... policy will gather at the 3rd Marine Board Forum in ... Board has convened this flagship event on the understanding that ...
Cached Biology News:Scientists trace evolutionary history of what mammals eat 2Live fast, die young 2New technologies for a blue future 2
Eagle's Ham's amino acids; EHAA...
... IRsolution software provides quick and easy operation ... with Windows-based control. The software is ... FDA 21 CFR Part 11 regulations, and ... measurement. IRsolutions versatility enables use in ...
... introduce random mutations to the gene supplied by ... into a vector of choice to obtain a ... can be set to a desired value within ... 106-108. Mutations can be restricted to a ...
... EVOlyzer is Tecans new Enzyme-Linked Immunosorbent Assay ... Freedom EVOlyzer is a dedicated EVO platform ... reader, washer and incubation units operated by ... EVOlyzer is available in three sizes - ...
Biology Products: